Motif Bio announces positive top-line data in antibiotic trial

Antibiotics specialist Motif Bio today announced positive top-line results from REVIVE-2, a Phase III trial evaluating the candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).

The trial met the primary endpoint of non-inferiority compared to vancomycin, the current standard of care, at the early time point of 48 to 72 hours after the start of administration.

The company says it expects to submit for regulatory approval in the first quarter of 2018.